Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

4094 results

Sort By:

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

Study ID: NCT04266730
Start Date: 2025-12-22
End Date: 2033-06-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

6

Intervention / Treatment

Panda-Vac

Pembrolizumab

Sponsor

UNC Lineberger Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Study ID: NCT06594939
Start Date: 2025-06
End Date: 2029-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

31

Intervention / Treatment

Polatuzumab Vedotin

Mosunetuzumab

Cyclophosphamide

Doxorubicin

Prednisone

Freak

Sponsor

Medical College of Wisconsin

Source: clinicaltrials.gov

Share:
Add to list

Music During Allogeneic Stem Cell Transplant Hospitalization

Study ID: NCT06679530
Start Date: 2025-12-01
End Date: 2027-12-25
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

35

Intervention / Treatment

Mindful Music Listening (MML)

Sponsor

University of Colorado, Denver

Source: clinicaltrials.gov

Share:
Add to list

The Efficacy and Safety of Narlumosbart in Combination with Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined with Immunotherapy in Patients with Bone Metastases from Advanced Non-small Cell Lung Cancer

Study ID: NCT06738160
Start Date: 2025-05-20
End Date: 2028-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

27

Intervention / Treatment

Narlumosbart

Sponsor

Fudan University

Source: clinicaltrials.gov

Share:
Add to list

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Study ID: NCT05700448
Start Date: 2025-06
End Date: 2028-11
Study Type

Interventional

Study Phase

Phase3

No. of Participants

150

Intervention / Treatment

Sugemalimab

Placebo

Pegaspargase

Gemcitabine

Oxaliplatin

Sponsor

CStone Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

The Prognostic Role of Fibrinogen to Albumin Ratio in Acute Leukemia Patients

Study ID: NCT06668948
Start Date: 2025-10-01
End Date: 2025-12-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

90

Intervention / Treatment
Sponsor

Assiut University

Source: clinicaltrials.gov

Share:
Add to list

U-POEM vs CO2-POEM

Study ID: NCT06918730
Start Date: 2025-05-23
End Date: 2026-07-23
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

36

Intervention / Treatment

U-poem

CO2-POEM

Sponsor

AdventHealth

Source: clinicaltrials.gov

Share:
Add to list

Cerebral Hemodynamics and Oxygenation in Critically Ill Patients

Study ID: NCT04690530
Start Date: 2026-03-01
End Date: 2027-03-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

mechanical ventilation

Sedation

Sponsor

Nice University Hospital Center

Source: clinicaltrials.gov

Share:
Add to list

Herbs & Supplements in Breast Cancer Usage, Impact, and Personalized Approaches for Diverse Populations

Study ID: NCT06926530
Start Date: 2025-06
End Date: 2025-10
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

240

Intervention / Treatment

No intervention

Sponsor

Case Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Study ID: NCT06581848
Start Date: 2025-05-01
End Date: 2030-05-29
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

150

Intervention / Treatment

Follower

Sponsor

Pfizer

Source: clinicaltrials.gov

Share:
Add to list